CDKN2A and cancer: The whole‐genome sequencing of 129 OACs by the ICGC demonstrated that most of the genes in this panel are mutated at a low frequency in the cancer (1–16%; SMAD4 [16%], CDKN2A [15%]), compared with the higher rate of TP53 mutation (81%) 20.